BiotechTube
Contera Pharma

Contera Pharma

Copenhagen, Denmark· Est.
conterapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $22.5M

Overview

Contera Pharma is a private, clinical-stage biotech company based in Hørsholm, Denmark, pioneering RNA-targeting therapeutics for neurological disorders. Its core asset is a proprietary discovery platform that integrates data for a precision medicine approach to identify and validate novel targets. The company has advanced its lead asset, CP-012 for Parkinson's disease, to Phase 1b with positive topline results, and is pursuing strategic partnerships, notably a 2025 research collaboration with Lundbeck, to expand its pipeline and accelerate development.

Neurological Disorders

Technology Platform

Proprietary discovery platform integrating external and internal data sources for a precision medicine approach to identify and select human disease-validated RNA drug discovery targets, primarily for neurological disorders.

Funding History

2
Total raised:$22.5M
Series A$20M
Seed$2.5M

Opportunities

The significant unmet need in neurological disorders like Parkinson's disease and rare conditions like Canavan disease presents a large and growing market.
The strategic collaboration with Lundbeck provides validation, funding, and expertise to accelerate platform output and pipeline development.
The expanding RNA therapeutics field offers a receptive environment for novel, validated modalities.

Risk Factors

High risk of clinical failure inherent in neurology drug development, even after positive early-stage results.
Dependence on future financing rounds or partnership milestones to fund costly later-stage trials, posing dilution or funding risks.
Intense competition in both the RNA therapeutics and neurology spaces from larger, resource-rich companies.

Competitive Landscape

Contera operates in the competitive RNA therapeutics space, competing with large biopharma (e.g., Ionis, Biogen, Roche) and biotechs focused on neurology. It also faces competition from companies developing novel Parkinson's disease therapies targeting motor complications. Its differentiation lies in its specialized discovery platform for CNS RNA targets and its strategic partnership with a CNS specialist, Lundbeck.

More companies in RNA Therapeutics (non-mRNA) →More companies in Denmark →